Literature DB >> 10987712

Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.

S Chen1, T Sorrell, G Nimmo, B Speed, B Currie, D Ellis, D Marriott, T Pfeiffer, D Parr, K Byth.   

Abstract

A prospective population-based study was conducted in Australia and New Zealand during 1994-1997 to elucidate the epidemiology of cryptococcosis due to Cryptococcus neoformans var. neoformans (CNVN) and C. neoformans var. gattii (CNVG) and to relate clinical manifestations to host immune status and cryptococcal variety. The mean annual incidence per 10(6) population was 6.6 in Australia and 2.2 in New Zealand. Of 312 episodes, CNVN caused 265 (85%; 98% of the episodes in immunocompromised hosts) and CNVG caused 47 (15%; 44% of the episodes in immunocompetent hosts). The incidence of AIDS-associated cases in Australia declined annually (P<.001). Aborigines in rural or semirural locations (P<.001) and immunocompetent males (P<.001) were at increased risk of CNVG infection. Cryptococcomas in lung or brain were more common in immunocompetent hosts (P< or =.03) in whom there was an association only between lung cryptococcomas and CNVG. An AIDS-associated genetic profile of CNVN serotype A was confirmed by random amplification of polymorphic DNA analysis. Resistance to antifungal drugs was uncommon. The epidemiology of CNVN infection has changed substantially. Clinical manifestations of disease are influenced more strongly by host immune status than by cryptococcal variety.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987712     DOI: 10.1086/313992

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  155 in total

1.  Cryptococcus infection in tropical Australia.

Authors:  Adam Jenney; Kishan Pandithage; Dale A Fisher; Bart J Currie
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis.

Authors:  Spinello Antinori; Anna Radice; Laura Galimberti; Carlo Magni; Marco Fasan; Carlo Parravicini
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

3.  Cryptococcus gattii Infection Presenting as an Aggressive Lung Mass.

Authors:  Shuwei Zheng; Thuan Tong Tan; Jaime Mei Fong Chien
Journal:  Mycopathologia       Date:  2017-12-06       Impact factor: 2.574

4.  A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada).

Authors:  S E Kidd; F Hagen; R L Tscharke; M Huynh; K H Bartlett; M Fyfe; L Macdougall; T Boekhout; K J Kwon-Chung; W Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-30       Impact factor: 11.205

5.  The Added Value of Longitudinal Imaging for Preclinical In Vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis.

Authors:  Greetje Vande Velde; Uwe Himmelreich; Liesbeth Vanherp; Jennifer Poelmans; Amy Hillen; Guilhem Janbon; Matthias Brock; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

6.  Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.

Authors:  Naureen Iqbal; Emilio E DeBess; Ron Wohrle; Ben Sun; Randall J Nett; Angela M Ahlquist; Tom Chiller; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

7.  Clinical characteristics and predictors of mortality for Cryptococcus gattii infection in dogs and cats of southwestern British Columbia.

Authors:  Colleen Duncan; Craig Stephen; John Campbell
Journal:  Can Vet J       Date:  2006-10       Impact factor: 1.008

8.  Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Nathan P Wiederhold; Annette W Fothergill; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 9.  Phenotypic switching of Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Neena Jain; Bettina C Fries
Journal:  Mycopathologia       Date:  2008-06-21       Impact factor: 2.574

10.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.